3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
993
Neoplasms
852
Carcinoma, Non-Small-Cell Lung
845
Prostatic Neoplasms
528
Neoplasm Metastasis
501
Leukemia, Myeloid, Acute
489
Melanoma
456
Colorectal Neoplasms
447
Multiple Myeloma
441
Lung Neoplasms
422
Pancreatic Neoplasms
353
Recurrence
350
Lymphoma
350
Ovarian Neoplasms
341
Lymphoma, Non-Hodgkin
329
Leukemia
324
Leukemia, Lymphocytic, Chronic, B-Cell
302
Precursor Cell Lymphoblastic Leukemia-Lymphoma
271
Carcinoma, Renal Cell
256
Head and Neck Neoplasms
246
Brain Neoplasms
245
Carcinoma, Hepatocellular
234
Glioblastoma
232
Squamous Cell Carcinoma of Head and Neck
231
Myelodysplastic Syndromes
231
Lymphoma, Large B-Cell, Diffuse
228
Lymphoma, Follicular
219
Colonic Neoplasms
191
Stomach Neoplasms
182
Rectal Neoplasms
175
Interventions
SLC-0111
1
IFL protocol
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
Metastatic Pancreatic Ductal Adenocarcinoma
×
Clear all
NCT03450018
2024-05-24
SLC-0111-17-01
British Columbia Cancer Agency
Phase 1/2
Terminated
6 enrolled
NCT03331640
2022-01-11
PANTHEON
AIO-Studien-gGmbH
Phase 2
Terminated
67 enrolled